The European Organisation for Rare Diseases (EURORDIS) has given its annual Company Award for medical innovation in rare diseases to Celgene.
The award recognises the biotech firm’s leading position in the treatment of orphan diseases, as well as its dialogue with patient groups.
Celgene has 17 orphan drug designations from the EMA, including products to treat types of leukaemia and myeloma, and is currently developing products to treat 45 rare diseases.
Orphan diseases are defined by the EMA as conditions affecting no more than five per 10,000 people. ‘Orphan drugs’ developed to treat them have a special regulatory status.
EURORDIS is the largest European patient organisation in the field of rare diseases. Its awards recognise outstanding contributions by companies, researchers and others to reducing the impact of rare diseases on people’s lives.
“We are honoured to receive the EURORDIS Company Award for our work in rare diseases, which is a testament to the strong partnerships we have throughout Europe with the people focused on treatment options for some of the most difficult-to-study and difficult-to-treat conditions,” said Stefano Portolano, Celgene’s Vice President for Haematology, Europe.
“In the nearly 13 years since the Orphan Drug Regulation was enacted, there has been growing recognition of the need for treatments for rare diseases that help patients live longer and higher quality lives. Celgene is proud to be recognised for its contributions in this area.”
Yann Le Cam, CEO of EURORDIS, commented: “We are proud that the rare disease community is becoming a model for multi-stakeholder partnership and international collaboration as well as for solidarity and unity throughout Europe.”
Celgene Corporation, based in the US with a European subsidiary based in Switzerland, specialises in developing drugs to treat cancer and inflammatory diseases through gene and protein regulation.